Clonazepam is NOT recommended for treating MS-related symptoms
The evidence provided does not support using clonazepam for multiple sclerosis symptom management. While one very old study from 1977 showed clonazepam had some efficacy for spasticity in MS patients, this evidence is outdated and contradicted by more recent safety data showing significant risks in this population 1.
Why Clonazepam Should Be Avoided in MS
Safety Concerns Specific to MS Patients
Recent research demonstrates that patients with progressive MS experience increased sensitivity to benzodiazepines like clonazepam, with heightened risk of adverse effects even at low doses 2. The 2020 CRISP trial found that MS patients with chronic spastic ataxic gait experienced acute intoxicant effects and worsening mobility with benzodiazepine-class medications, effects that resolved only upon drug cessation 2.
Known Adverse Effects in Neurological Populations
The FDA label and clinical guidelines consistently warn about problematic side effects that are particularly concerning for MS patients 3:
- Morning sedation and gait imbalance/falls - critical concerns given that MS patients already have baseline mobility impairment 4
- Cognitive disturbances including delirium and amnesia - problematic as cognitive dysfunction is already common in MS 5
- Motor incoordination - compounds existing MS-related motor deficits 5
- Risk of confusion and falls with potential for subdural hematoma 5
Clonazepam is listed on the American Geriatrics Society Beers Criteria as a potentially inappropriate medication in older adults, and many MS patients fall into this age category 4.
Better Alternatives for MS Symptom Management
For Spasticity
- Baclofen remains the first-line agent for spasticity in MS, with the 1977 study showing comparable or superior efficacy to clonazepam specifically for spinal spasticity 1
- Tizanidine is another established option
For Anxiety
- Duloxetine or other SNRIs are safer alternatives with established efficacy profiles
- SSRIs for mood/anxiety management without the fall risk and cognitive impairment
For Sleep Disturbances
- Melatonin 3-15 mg is safer with minimal sedation 4
- Trazodone 25-100 mg at bedtime 6
- Sleep hygiene and cognitive-behavioral interventions 6
Critical Clinical Pitfall
The 2024 MENACTRIMS consensus guidelines for MS diagnosis and treatment make no mention of benzodiazepines as recommended therapy 7, which is telling given their comprehensive review of MS management. The epidemiological data shows that benzodiazepine use is already 1.49-fold higher in MS patients compared to matched controls, and this use is often chronic 8, suggesting inappropriate prescribing patterns that should be corrected rather than perpetuated.
If a patient with MS is already taking clonazepam, do not abruptly discontinue it due to seizure and withdrawal risks 3. Instead, implement a gradual taper while transitioning to safer alternatives appropriate for their specific symptoms.